Management of cardiovascular disease in Turner syndrome

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1631-41. doi: 10.1586/erc.09.149.

Abstract

As a result of the multitude of potential comorbidities, patients with Turner syndrome require lifelong cardiac care. This review summarizes the current state of knowledge of the cardiovascular pathology present in patients with Turner syndrome and outlines recommendations for cardiac care from birth through to adulthood.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / genetics
  • Comorbidity
  • Female
  • Heart Defects, Congenital / drug therapy
  • Heart Defects, Congenital / epidemiology
  • Heart Defects, Congenital / genetics
  • Hormone Replacement Therapy
  • Human Growth Hormone / therapeutic use
  • Humans
  • Practice Guidelines as Topic
  • Turner Syndrome / drug therapy
  • Turner Syndrome / epidemiology*
  • Turner Syndrome / genetics

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Human Growth Hormone